An interventional study of SHS-derived CDS in Sexually Transmitted Diseases, sponsored by Children's National Research Institute. Recruiting at 1 site in United States. Open to participants aged 15 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Children's National Research Institute · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 283 studies in Sexually Transmitted Diseases with a site in United States — 32 open to participants now, 42 under way, 1 of them phase 3. Sexually Transmitted Diseases · United States.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, this one is the 5th largest by planned enrollment of the 251 interventional ones that give a count, is one of 14 that started in 2023, is one of 190 with no phase, reaches primary completion later than 10 of the 41 other live ones, and was the 209th registered.
525 studies on the registry are indexed under Sexually Transmitted Diseases; 79 are open to participants now.
Browse Sexually Transmitted Diseases studies →32 of the 283 studies in Sexually Transmitted Diseases with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
Westat · Sites in United States
Ages 13–24 · Men only · Healthy volunteers
Emory University · Sites in United States
Women only · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 13–21 · Men only · Healthy volunteers
Westat · Sites in United States
Ages 13–29 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Sexually Transmitted Diseases studies recruiting now, 30 (61%) set no upper age limit and 17 (35%) stop at 75 or younger; 23 take children under 18; 33 take healthy volunteers.
This study: 15 Years to 21 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 29 · Phase 3 15 · Phase 4 12
First in 1993; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18,500 is above the median of 449 across 426 interventional studies indexed under Sexually Transmitted Diseases.
Median enrollment 400 across the 251 interventional studies, 280 across the 30 observational. Of the 227 that completed or were terminated, 76 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 283 have an industry lead sponsor. The 10 most frequent:
Children's National Research Institute is the lead sponsor of 127 studies on the registry; 45 are open to participants now.
Children's National Research Institute has 3 studies filed under Sexually Transmitted Diseases — fewer than ten, so there is no comparison to draw.
16 of the studies in Sexually Transmitted Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06183502Emory UniversityHIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men | 2026-11 |
| NCT07089836American Laboratory Products CompanyThis Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests. | 2026-12 |
| NCT07281599QurasenseEvaluation of the Q-Pad hrHPV Test System for Identifying Precancer | 2026-12-31 |
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
| NCT04372875Children's National Research InstituteHealth Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 283 studies in Sexually Transmitted Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We will compare differences in sexually transmitted infection (STI) detection rates between sexual health survey (SHS)-derived electronic clinical decision support (CDS) versus usual care (e.g. no provision of CDS) using an interrupted time series design. We hypothesize that population-based STI detection rates will be higher when SHS-derived electronic CDS is provided compared to usual care. Secondary analysis will include a comparison of STI detection rates by sexual risk strata (high risk vs. at risk) and race/ethnicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All adolescents seen in the emergency department that meet eligibility criteria will be offered the sexual health survey (SHS) during the pragmatic trial.
Behavioral: SHS-derived CDS
All adolescents seen in the emergency department that meet eligibility criteria prior to implementation of SHS-derived CDS.
This intervention will provide electronic clinical decision support for adolescents who screen at risk or at high risk of an STI.
Chlamydia trachomatis (CT) / Neisseria gonorrhoeae (GC) detection rates
Proportion of encounters during which patients test positive for CT/GC; measured by urine-based nucleic acid amplification tests.
Time frame: 3-7 days after emergency department (ED) visit
STI rates by race/ethnicity
Change in STI rates by race/ethnicity
Time frame: 3-7 days after ED visit
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.
Of 173 non-industry interventional studies with no phase under Sexually Transmitted Diseases, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 45 months is above that.
Counting every sponsor, half of 183 studies reached it within 31 months; a quarter within 16 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sexually Transmitted Diseases →
Children's National Research Institute →